![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The companies are collaborating to apply Artificial Intelligence (AI) technology and advanced imaging strategies to further the development of AR-67, a third generation Camptothecin, in patients with recurrent glioblastoma multiforme (reGBM).
Lead Product(s): Silatecan
Therapeutic Area: Oncology Product Name: AR-67
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Vivacitas Oncology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership May 03, 2021
Details:
IAG, a leading medical imaging company, will work closely with CNS during the Berubicin clinical trials to provide critical imaging services, its proprietary platform DYNAMIKA and imaging data analysis.
Lead Product(s): Berubicin Hydrochloride
Therapeutic Area: Oncology Product Name: RTA 744
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: CNS Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership September 24, 2020